Steve Webster
Analyst · KeyBanc Capital Markets. Please go ahead
Thanks, Andy. I'll begin on Slide 5 with a summary of our sales results by end market. I'm pleased to report that we generated year-over-year sales growth of 4% during the quarter. Defense, first response and health care sales grew 32%, driven by robust military demand as we saw in the fourth quarter. Sales of magnesium alloys for defense aerospace and chemical kits both increased, while SCBA, medical oxygen and zirconium pharmaceutical applications also contributed to sales growth in this end market category. Transportation sales decreased 10%. We continue to benefit from the ongoing recovery in the aerospace and automotive markets, as Andy mentioned, magnesium alloys for commercial aerospace and zirconium auto-catalysis materials moved higher. However, after realizing accelerating sales in the prior two quarters, alternative fuel sales slowed, which was disappointing but not entirely surprising given the unevenness inherent in this early stage market. General industrial sales declined 8%, with mixed performance by product type. Zirconium oxide and chemical catalysis both saw growing demand. However, these gains were more than offset by contraction in oil and gas and magnesium photo-engraving plates. We discussed the backdrop for these categories on our prior call. We are pleased with the resilience demonstrated by several key areas of our product portfolio and additional gains in some secular growth end markets realized during the quarter. Now please turn to Slide 6 for a summary of our consolidated first quarter financial results. First quarter sales of $101.3 million increased $4.3 million from the prior year. This growth was driven by $10 million of price action to address rising input costs, partially offset by adverse volume and mix as well as foreign exchange headwinds. Consolidated adjusted EBITDA of $11.3 million in quarter one decreased $4.8 million from the prior year. Volume mix negatively impacted our performance by $1.7 million on a year-over-year basis, with foreign exchange a partial positive offset of $0.8 million. Growth-related headcount investment and higher legal expenses, as discussed in our quarter four call also reduced profit for the period. We remain focused on addressing pass-through from input cost inflation and enacting efficiency gains to best navigate the current demand environment. Now let's turn to our segment results on Slide 7. Elektron sales of $59.8 million increased 10% from a year ago again driven by our further push to pass through inflation, partially offset by volume mix of $0.9 million and foreign exchange headwinds. However, Elektron's EBITDA of $8.8 million decreased by 34%, largely due to volume and mix as well as the impact of legal and other costs. Advanced recovery of inflationary costs during 2022 inevitably make year-over-year comparisons challenging for this segment. Gas Cylinder sales of $41.5 million decreased 2% due to adverse impacts of $1.5 million from foreign exchange and $2.5 million from volume mix, which offset a $3.1 million positive impact from cost pass-through. EBITDA of $2.5 million contracted 7% from $2.7 million in the prior year due largely to the impact of volume mix. Encouragingly, cost pass-through fully offset inflation in the quarter, demonstrating traction in our effort to turn around and ultimately restore margins in this business. We also benefited from the implementation of fixed cost savings initiatives with additional cost actions planned in the coming quarters. Now I'd like to discuss our updated 2023 outlook on Slide 8. Balancing the demand picture Andy detailed earlier, with our internal assets and a deficiency, we continue to target 2023 full year adjusted EPS of $1.15 to $1.35. Though we have lowered our current 2023 projection for sales growth to 4% to 7%, down 6% to 10% in our prior call, we're focusing on margin and cost control to achieve our EPS objectives. We expect EPS to accelerate to the mid-$0.20 range in quarter two. We are also bringing increased focus on cash generation. While we are maintaining our 100% goal for adjusted free cash flow conversion, this is somewhat challenged by ongoing pressure on inventory, which impacted cash performance in the first quarter. That said, a quarter on cash outflow does reflect typical seasonal norms for our business and we expect significant sequential improvement going forward. Despite the mixed cyclical backdrop, we are maintaining our growth-related CapEx plans, which are supported by our full year profit expectations and our sound capital position. Furthermore, I'm pleased to confirm that we achieved the successful buyout of our U.S. design benefit pension plan in quarter one for $2.3 million, less than the $3.5 million we outlined previously. Also related to the balance sheet, I want to highlight that we plan to repay our $25 million private placement loan due in June of this year with proceeds from our $125 million revolver. Pro forma for this anticipated loan repayment, we would hold nearly $60 million of immediate liquidity, which remains robust relative to our capital planning and the evolving macro environment. I look forward to updating you on our progress to not only deliver on our profit objectives, but to further invest in positioning our business for long-term growth. Now I'd like to hand the call back over to Andy. Andy?